Brief: CytoDyn Says Leronlimab Trial Demonstrated 24% Reduction In Mortality For Critically Ill COVID-19 Patients

Cytodyn

08/03/2021 11:38

March 8 (Reuters) - Cytodyn Inc  CYDY.PK :
    * CYTODYN’S PHASE 3 TRIAL DEMONSTRATES SAFETY, A 24%
REDUCTION IN
MORTALITY AND FASTER HOSPITAL DISCHARGE FOR MECHANICALLY
VENTILATED CRITICALLY ILL COVID-19 PATIENTS TREATED WITH
LERONLIMAB
    * CYTODYN - PHASE 3 TRIAL OF LERONLIMAB DEMONSTRATED
CONTINUED
SAFETY, SUBSTANTIAL IMPROVEMENT IN SURVIVAL RATE
    * CYTODYN - AVERAGE LENGTH OF HOSPITAL STAY REDUCED BY 6
DAYS FOR
PATIENTS WHO GOT LERONLIMAB WITH STANDARD OF CARE VERSUS PLACEBO
PATIENTS WHO RECEIVED SOC ONLY
    * CYTODYN INC - PHASE 3 TRIAL OF LERONLIMAB DEMONSTRATED
FASTER
HOSPITAL DISCHARGE IN CRITICALLY ILL COVID-19 PATIENTS
    * CYTODYN INC - CONCURRENTLY WORKING WITH REGULATORS TO
EXPEDITE
LERONLIMAB'S APPROVAL TO TREAT COVID-19

Source text for Eikon:  ID:nGNX2Ksxzp 
Further company coverage:  CYDY.PK 

 ((Reuters.Briefs@thomsonreuters.com;))